News

December 8, 2022
Oncolytics Biotech’s® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
December 1, 2022
Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer
November 21, 2022
Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium
November 10, 2022
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study’s Pancreatic Cancer Cohort
November 7, 2022
Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
November 7, 2022
Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting
October 27, 2022
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
October 5, 2022
Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
September 7, 2022
Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors
August 11, 2022
Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.com

Email Alerts Sign-Up

Secret Link